Piper Sandler Rates Oruka Therapeutics Overweight with $75 Price Target
Piper Sandler gives Oruka Therapeutics an Overweight rating, highlighting its unique antibody portfolio, ORKA-001 validation, and a promising 2026 catalyst-rich year.
/ 4 items
#ORKA↓
Guggenheim Bullish on Oruka Therapeutics with $60 Target
Guggenheim starts coverage of Oruka Therapeutics with Buy rating and $60 target, praising its longer-acting antibody drugs for chronic inflammation treatment.
Oruka Therapeutics Stock Surges on Rival's Mixed Drug Trial Results
Oruka Therapeutics shares jump 30% as analysts predict gains following competitor MoonLake's Phase 3 results.
Oruka's Psoriasis Breakthrough and $180M Investment
ORKA-001, Oruka's new psoriasis drug, shows a 100-day half-life, making once-a-year dosing possible. It aims for higher skin clearance and long-term remission with a good safety profile. Phase 2 data is expected in late 2026. This could redefine treatment!